Sandoz Launches Act4Biosimilars Action Plan to Improve Access to Biosimilar Medicines
Shots:
- The company launched Act4Biosimilars Action Plan, a global roadmap intended to increase patient access to biological medicines. The action plan has been designed to increase global biosimilar adoption by 30 percentage points in 30+ countries by 2030
- The Action Plan introduced 12 key initiatives across the 4 areas: approvability, acceptability, accessibility, and affordability. The steps are designed to help local stakeholders create a more favorable environment for biosimilars
- The Action Plan will incl. a series of reports identifying key challenges by region with the first region being the Americas. Key challenges incl. confusion among patients & healthcare professionals around the interchangeability of regulatory guidelines in the US
Ref: Novartis | Image: Sandoz
Related News:- Sandoz Reports the EMA Acceptance of MAA for Proposed Biosimilar Denosumab
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
